Genomic Profiling of Intrahepatic Cholangiocarcinoma: Refining Prognosis and Identifying Therapeutic Targets

New Routes to Targeted Therapy of Intrahepatic Cholangiocarcinomas Revealed by Next-Generation Sequencing

(2014) J. S. Ross et al.   ONCOLOGIST

Incidence and prognostic impact of KRAS and BRAF mutation in patients undergoing liver surgery for colorectal metastases

(2013) Georgios Karagkounis et al.   CANCER

Integrative Molecular Analysis of Intrahepatic Cholangiocarcinoma Reveals 2 Classes That Have Different Outcomes

(2013) Daniela Sia et al.   GASTROENTEROLOGY

Molecular profiling of cholangiocarcinoma shows potential for targeted therapy treatment decisions

(2013) Jesse S. Voss et al.   HUMAN PATHOLOGY

The frequency of KRAS and BRAF mutations in intrahepatic cholangiocarcinomas and their correlation with clinical outcome

(2013) Scott Robertson et al.   HUMAN PATHOLOGY

Exome sequencing identifies distinct mutational patterns in liver fluke–related and non-infection-related bile duct cancers

(2013) Waraporn Chan-on et al.   NATURE GENETICS

Exome sequencing identifies frequent inactivating mutations in BAP1, ARID1A and PBRM1 in intrahepatic cholangiocarcinomas

(2013) Yuchen Jiao et al.   NATURE GENETICS

Intrahepatic cholangiocarcinoma: pathogenesis and rationale for molecular therapies

(2013) D Sia et al.   ONCOGENE

(R)-2-Hydroxyglutarate Is Sufficient to Promote Leukemogenesis and Its Effects Are Reversible

(2013) J.-A. Losman et al.   SCIENCE

Identification of Targetable FGFR Gene Fusions in Diverse Cancers

(2013) Yi-Mi Wu et al.   Cancer Discovery

Genetic profiling of intrahepatic cholangiocarcinoma

(2012) Jesper B. Andersen et al.   CURRENT OPINION IN GASTROENTEROLOGY

Isocitrate dehydrogenase 1 and 2 mutations in cholangiocarcinoma

(2012) Benjamin R. Kipp et al.   HUMAN PATHOLOGY

Exome sequencing of liver fluke–associated cholangiocarcinoma

(2012) Choon Kiat Ong et al.   NATURE GENETICS

Survival in BRAF V600–Mutant Advanced Melanoma Treated with Vemurafenib

(2012) Jeffrey A. Sosman et al.   NEW ENGLAND JOURNAL OF MEDICINE

Mutations in isocitrate dehydrogenase 1 and 2 occur frequently in intrahepatic cholangiocarcinomas and share hypermethylation targets with glioblastomas

(2012) P Wang et al.   ONCOGENE

Genomic and Genetic Characterization of Cholangiocarcinoma Identifies Therapeutic Targets for Tyrosine Kinase Inhibitors

(2011) Jesper B. Andersen et al.   GASTROENTEROLOGY

Exploring genomic profiles of hepatocellular carcinoma

(2011) Hyun Goo Woo et al.   MOLECULAR CARCINOGENESIS

Frequent Mutation of Isocitrate Dehydrogenase (IDH)1 and IDH2 in Cholangiocarcinoma Identified Through Broad-Based Tumor Genotyping

(2011) D. R. Borger et al.   ONCOLOGIST

KRAS and PIK3CA but not BRAF genes are frequently mutated in Chinese cholangiocarcinoma patients

(2010) Rui Feng Xu et al.   BIOMEDICINE & PHARMACOTHERAPY

The Common Feature of Leukemia-Associated IDH1 and IDH2 Mutations Is a Neomorphic Enzyme Activity Converting α-Ketoglutarate to 2-Hydroxyglutarate

(2010) Patrick S. Ward et al.   CANCER CELL

Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine

(2010) Dora Dias-Santagata et al.   EMBO Molecular Medicine

Genetics of Biliary Tract Cancers and Emerging Targeted Therapies

(2010) Aram F. Hezel et al.   JOURNAL OF CLINICAL ONCOLOGY

Cisplatin plus Gemcitabine versus Gemcitabine for Biliary Tract Cancer

(2010) Juan Valle et al.   NEW ENGLAND JOURNAL OF MEDICINE

Intrahepatic Cholangiocarcinoma

(2010) George A. Poultsides et al.   SURGICAL CLINICS OF NORTH AMERICA

Pathogenesis of hepatocellular carcinoma and molecular therapies

(2009) Beatriz Mínguez et al.   CURRENT OPINION IN GASTROENTEROLOGY

Cancer-associated IDH1 mutations produce 2-hydroxyglutarate

(2009) Lenny Dang et al.   NATURE

RarePIK3CA hotspot mutations in carcinomas of the biliary tract

(2008) Marc-Oliver Riener et al.   GENES CHROMOSOMES & CANCER

Epidemiology, risk factors, and pathogenesis of cholangiocarcinoma

(2008) S.A. Khan et al.   HPB